ALDH2 and Hepatic steatosis: AD-9308 treatment reduced the extent of hepatic steatosis (Fig. 5j, k, l) and the levels of hepatic triglycerides contents in both Aldh2 KI and WT mice in a dose-dependent manner (Fig. 5m).